Science, medicine, and the future. The future of the management of ischaemic heart disease

British Medical Journal

Volumn 314, Issue 7077, 1997, Pages 356-359

  Crossman, David ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Department of Clinical Cardiology ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC RISK; HEALTH CARE COST; HEART TRANSPLANTATION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RESTENOSIS; SHORT SURVEY; TRANSLUMINAL CORONARY ANGIOPLASTY; ANIMAL; GENETIC PREDISPOSITION; HEART MUSCLE ISCHEMIA; HUMAN; RECURRENT DISEASE; REVIEW; TRANSGENIC ANIMAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANIMALS, GENETICALLY MODIFIED; GENETIC PREDISPOSITION TO DISEASE; HEART TRANSPLANTATION; HUMANS; MYOCARDIAL ISCHEMIA; RECURRENCE;

EID: 0031068166     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.314.7077.356     Document Type: Short Survey

References (18)

1. Compendium of health statistics. 9th ed. London: Office of Health Economics, 1995.
2. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
3. Maseri A, Biasucci LM, Liuzzo G. Inflammation in ischaemic heart disease. BMJ 1996;312:1049-50.
4. Duff GW. Molecular genetics of cytokines. In: Thomson A, ed. The cytokine handbook. 2nd ed. London: Academic Press, 1994:21-31.
5. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-10.
6. Savill J. Molecular genetic approaches to understanding disease. BMJ;314:126-9.
7. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
8. Fishman DL, Leon M, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
9. Serruys PW, de Jaeger P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary disease. N Engl J Med 1994;331:489-95.
10. Hamon M, Bauters C, McFadden EP, Wernert N, Lablanche JM, Dupuis B, et al. Restenosis after coronary angioplasty. Eur Heart J 1995;16(suppl 1):33-48.
11. Appelman YE, Piek JJ, Strikwerda S,Tijssen JG, de Feyter PJ, David GK, et al. Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary disease. Lancet 1996;347:79-84.
12. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary disease. The CAVEAT Study Group. N Engl J Med 1993;329:221-7.
13. Powell JS, Clozel J-P, Muller RKM, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.
14. Multicentre European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (Mercator) Study Group. Does the new angiotensin-converting enzyine inhibitor cilazapril prevent restenosis after percutaneous transluminal angioplasty? Results of the Mercator study: a multicentre, double-blind, placebo-controlled trial with cilazapril. Circulation 1992;86:100-10.
15. Wang X, Ruffolo RR, Feurstein GZ. mRNA differential display: application in the discovery of novel pharmacological targets. Trends in Pharmac Sci 1996;17:276-9.
16. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using polymerase chain reaction. Genomics 1996;5:874-9.
17. Warrens AN, Dorling A, Lechler RI. The prospects for xenotransplantation. QJ Med 1996;89:885-91.
18. McCurry KR, Kooyman DL, Alvardo CG, Cotterell AH, Martin MJ, Logan J, et al. Human complement regulatory proteins protect swine to primate xenografts from humoral injury. Nature Medicine 1995;1:423-7.